Table 2 Clinical features of the participants who contributed synovial fluid
Characteristics | RA | OA |
|---|---|---|
Number of participants | 30 | 30 |
Sex, male/female | 6/24 | 6/24 |
Age, mean (range) | 63.1 (32 to 88) | 75.3 (67 to 89) |
Disease duration (y), mean (range) | 13.0 (0.5 to 50) | NA |
Positive anti-CCP antibody, n (%) | 10 (83.3%)¶ | NA |
ESR (mm), mean (range) | 49.6 (4 to 116) | NA |
CRP (mg/dl), mean (range) | 3.1 (0 to 13.9) | NA |
MMP3 (ng/ml), mean (range) | 362.7 (43.2 to 800) | NA |
DAS28, mean (range) | 4.9 (2.2 to 7.1) | NA |
   SJC, mean (range) | 4.9 (0 to 17) | NA |
   TJC, mean (range) | 5.1 (0 to 27) | NA |
VAS | 52.1 (10 to 95) | NA |
Steinbrocker Stage, n | I: 3, II: 3, III: 5, IV: 19 | NA |
Steinbrocker Class, n | I: 1, II: 22, III: 7, IV: 0 | NA |
Kellgren/Lawrence grade, n | NA | I: 0, II: 0, III: 11, IV: 19 |
Medication, n (%) | Â | Â |
   Prednisolone | 20 (67%) | NA |
   Methotrexate | 15 (50%) | NA |
   Infliximab | 3 (10%) | NA |
   Eternercept | 1 (3.3%) | NA |
   Tocilizumab | 0 (0%) | NA |
   Tacrolimus | 2 (6.7%) | NA |
   Salazosulfapyridine | 8 (27%) | NA |
   Bucillamine | 6 (20%) | NA |
   Mizoribine | 1 (3.3%) | NA |
   Gold | 2 (6.7%) | NA |